VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma,  and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel.   Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…

Read More

Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…

Read More

Non-surgical treatment now available on Medicare Of the estimated 66,500 Australians living with aortic stenosis, 9 in 10 are not undergoing treatment each year for the potentially life-threatening disease. However, the inclusion of transcatheter aortic valve implantation (TAVI) on Medicare from July 1, 2022, is expanding access to the minimally invasive treatment option for all…

Read More

Almost 20,000 Australian men diagnosed each year with prostate cancer are being denied access to an innovative treatment on Medicare for the nation’s most common cancer in men. Two treatment options – low dose rate brachytherapy (LDR-brachytherapy) and external beam radiation therapy – are approved to treat prostate cancer in Australia by the medical regulator,…

Read More

An osteoporotic fracture occurs every three seconds worldwide.1 With more than 50 per cent of the world’s hip fractures expected to occur in the Asia Pacific (AP) region over the next two decades,2 the Asia Pacific Consortium on Osteoporosis (APCO) has launched a Bone Health QI Tool Kit today(May 24, 2022), to promote quality improvement…

Read More